Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Adicet Bio, Inc.

NASDAQ: ACET · Life Sciences · 4 alerts · CIK 1720580

Share price
$2.75Close, Nov 16
Market cap
$25.7M
Shares outstanding
9.36MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Adicet Bio, Inc. filings on SEC EDGAR ↗

8:16 AM ET 8-K
Clinical Trial Data

Adicet Bio Clinical Trial Data

Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.

Earnings call
Sep 28, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.